Introduction
Interferon (IFN)-␣ recombinant protein therapy is the first cytokine to be used clinically for cancer patients and has been shown to be effective in the treatment of several cancers including renal cell carcinomaa, hairy cell leukemia, malignant melanoma, basal cell carcinoma, and multiple myeloma. [1] [2] [3] However, long-term daily administration of IFN-␣ protein is required to maintain therapeutic efficacy, and some IFN-␣ protein clinical trials have been disappointing. 4 Ex vivo IFN-␣ gene therapy studies have demonstrated tumor inhibition and an elicited tumor-specific immune memory. [5] [6] [7] [8] [9] However, this approach is patient-specific and the application is time-consuming. Direct intratumoral injection of IFN-␣ to treat solid Renca, 10 basal cell carcinoma, 11 and heteroxenograft prostatic (PC-3) or hepatocellular carcinoma (Hep3B) 12 with the use of viral or nonviral delivery systems has demonstrated effective tumor suppression in mouse models in vivo, but the intratumoral approach is not practical for metastatic lesions and microscopic residual lesions after surgery. 2 or endostatin gene, also delivered by electro-injection. The increased therapeutic efficacy was associated with a high level and extended duration of IFN-␣ expression in muscle and serum. We also discovered that the high level of IFN-␣ expression correlated with increased expression levels of the antiangiogenic genes IP-10 and Mig in local tumor tissue, which may have led to the reduction of blood vessels observed at the local tumor site. Delivery of increasing doses (10-100 g) of IFN-␣ plasmid DNA by injection alone did not increase antitumor activity, whereas electroporation delivery of increasing doses (10-40 g) of IFN-␣ plasmid DNA did increase the survival time. Our data clearly demonstrate the potential utility of electroporation for delivery of gene therapy to muscle for the treatment of residual or disseminated tumors. Gene Therapy (2001) 8, 400-407.
Skeletal muscle is an attractive site for somatic gene delivery because of its large size, good capacity for protein synthesis, easy accessibility for intramuscular injection, and ability to take up plasmid after intramuscular administration. 13 Intramuscular injection of high-dose, but not low-dose, IFN-␣ gene using a syringe needle significantly inhibited B16F10 melanoma and glioma 261 growth in mice and reduced Cloudman melanoma tumor growth in vivo, 14 demonstrating the high level of IFN-␣ that is required to achieve therapeutic effect.
Electroporation is a highly effective method for increasing gene expression by creating transient pores in cell membranes through which plasmids can gain entry into the cell. Although electroporation delivery of reporter and therapeutic genes to muscle has been described by several groups over the past few years, [15] [16] [17] there are no data available to determine the therapeutic efficacy of such an approach in a tumor model.
IFN-␣ has several subtypes and multiple biological functions that control cell growth, modulate host immunity, and inhibit angiogenesis. [18] [19] [20] [21] The mechanisms of antitumoral cell proliferation and immunity modulation by IFN-␣ have been extensively examined, but the mechanism for antiangiogenesis is less well studied and only a few antiangiogenic genes regulated by IFN-␣ have been identified. [18] [19] [20] [21] [22] The expression of interferon inducible pro-401 tein-10 (IP-10) and monokine induced by IFN-␥ (Mig) have been known to be enhanced by IFN-␥ and inhibit angiogenesis in tumors in vivo, [23] [24] [25] [26] [27] [28] but it is not clear whether IFN-␣ will have a similar effect in vivo.
We used squamous cell carcinoma (SCCVII) in an immunocompetent mouse (C3H/HeJ) as a model for this study. We present data demonstrating that electro-injection of the IFN-␣ gene is a very powerful method for generating a high and durable level of gene expression. We also show that this method of delivering the IFN-␣ gene into muscle induces significant anti-SCCVII tumor growth by increasing the level of IFN-␣ expression, which may in turn inhibit tumor vascularization by inducing IP-10 and Mig expression.
Results
Increased gene expression in C3H/HeJ mice using electro-injection in muscle In an earlier study, we observed a two-to three-fold increase in the level of gene expression by electro-injection of plasmid DNA in the muscle of the CD1 mouse, using electroporation conditions of two 25-ms pulses at 375 V/cm field strength. 29 To determine whether the same results could be obtained in a murine tumor model, we determined enzyme activity after delivery of luciferase or secreted alkaline phosphatase (SEAP) gene to the muscle of the C3H/HeJ mouse, an immunocompetent mouse model, using 10 g of DNA for each muscle, with or without electroporation. As shown in Figure 1 , the level of luciferase expression in muscle reached 135 ng/mg total protein (Figure 1a ), which was more than 100-fold higher than that in the injection-only group. The maximum level of SEAP in serum was 285 ng/ml blood, which was reached on day 14 after delivery and was 100-fold higher than that in the injection-only group ( Figure  1b) . As expected, the magnitude of increase in gene expression in C3H/HeJ mice was similar to that which we observed in CD1 mice. The increased level of gene expression by electro-injection was correlated to the increased number of fiber cells transfected with exogenous DNA as determined by green fluorescent protein (GFP) expression (Figure 1c) . Thus, our delivery technique was applicable to this murine tumor model.
Inhibition of SCCVII tumor growth via electro-injection of IFN-␣ gene in muscle
Tumor growth in the animal group receiving 10 g of INF-␣ plasmid DNA injected by electroporation was significantly reduced, compared with that in either the syringe needle injection group or the control groups (empty plasmid with or without electroporation delivery), and the survival time was increased (P Ͻ 0.05; Figure 2a, b) . This result has been demonstrated in two independent experiments. Interestingly, either low-dose (10 g) or high-dose (100 g) IFN-␣ DNA plasmid by syringe needle injection alone did not enhance any antitumor activity (Figure 2a) . However, intramuscular electroinjection of high-dose IFN-␣ DNA (40 g) led to longer survival time than electro-injection of low-dose IFN-␣ plasmid DNA (10 g) (Figure 2b) .
We also determined whether IFN-␣ gene therapy using intramuscular electroporation delivery inhibited tumor growth with delayed treatment, wherein treatment was Gene Therapy started when the tumor volume was 30 mm 3 , or twice the size as in the above experiment. Although the reduction was not as dramatic as in the previous experiment, a 50% reduction in tumor growth was obtained with electroporation delivery (Figure 2c) . These data clearly demonstrate that although electro-injection of IFN-␣ was not able to eradicate the established SCCVII tumor in vivo, it was able to reduce significantly the rate of tumor growth.
High-level and extended gene expression in serum after electro-injection of IFN-␣ gene in muscle To determine whether the enhanced therapeutic efficacy of IFN-␣ by electroporation delivery directly correlates with IFN-␣ production, Western blot analysis was performed to analyze the level of IFN-␣ gene expression in both injected muscle tissue and serum. As expected, high levels of IFN-␣ gene expression were detected in both muscle and serum on day 3 after electro-injection. There was no detectable level of IFN-␣ expression in either muscle tissue or serum following injection alone ( Figure 3a) .
The duration of IFN-␣ gene expression after a single administration of IFN-␣ gene therapy was also determined. Serum was collected on days 1, 3 and 7. IFN-␣ protein was detectable in the serum of electro-injected mice at all three sampling times by Western blot analysis. However, it was not detected in mice receiving the injection without electroporation ( Figure 3b ). Clearly, the therapeutic efficacy of electroporation therapy could be attributed, at least in part, to the resulting high-level and extended expression of IFN-␣.
Inhibition of vascularization in tumor tissue after electroporation delivery of IFN-␣ gene in muscle
To determine the mechanism by which electroporation gene therapy with IFN-␣ inhibited tumor growth, a cytotoxic T lymphocyte (CTL) assay was performed. This showed no increase in tumor cell-lysing activity in either the electro-injected animals or controls (data not shown). However, immunostaining with anti-CD8 + T cell antibody and anti-endothelial cell marker CD31 antibody demonstrated a slightly increased number of infiltrating CD8 + T cells (P Ͼ 0.05) and significantly decreased vessel density (P Ͻ 0.05) after electroporation delivery of IFN-␣ gene in muscle ( Figure 4A -C). The tumor samples for immunostaining were obtained from mice killed 3 days after the second administration, with a week interval between administrations.
Enhanced expression of IP-10 and Mig after electroporation delivery of IFN-␣ gene in muscle
The slight increase in CD8 + T cell infiltration and decrease in vessel density in tumor observed in our study implicated a functionally active chemokine. It is known that IP-10 and Mig are regulated by IFN-␥ to chemo-attract immune cells and inhibit angiogenesis. [23] [24] [25] [26] [27] [28] To determine whether IP-10 and Mig were also up-regulated by IFN-␣ expression, we analyzed the levels of both Mig and IP-10 expression using Northern blot, quantifying the results by phosphorimager scanner. The expression levels of both Mig and IP-10 were increased by 1.8-to three-fold after electro-injection of a high dose (40 g) of INF-␣ ( Figure 5 ). At a low dose (10 g), the increase was about 1.3-to two-fold. Analysis of the level of vascular endothelial growth factor (VEGF) in serum showed that there was no difference with or without electroporation delivery of the IFN-␣ DNA plasmid (data not shown).
Comparison of different therapeutic genes for SCCVII tumor treatment with or without electroporation
We compared the delivery of IFN-␣ gene with the T cell proliferation-stimulating IL-2 gene, the known Mig-and IP-10-inducing IL-12 gene, and the known antiangiogenic endostatin gene, with or without electroporation, to determine their relative efficacy in reducing tumor growth. Using groups of five tumor-bearing mice for each gene, as described in Materials and methods, we were able to demonstrate that IFN-␣ and IL-12 gene therapy using intramuscular electroporation delivery had the most significant reduction in tumor growth ( Figure 6 ). IL-2 gene therapy via electro-injection showed some effect, but endostatin gene therapy showed no tumor inhibition.
Discussion
Treatment of disseminated malignancies is one of the most difficult tasks facing clinical oncologists. Thus, this remains the focus for optimizing existing cancer therapies and devising new ones. Muscle has been an attractive somatic delivery site for gene therapy. However, the low level of gene expression after injection of DNA plasmid into muscle has limited the development of this nonviral gene therapy approach. Efforts to increase the level of gene expression by improving the expression systems 13, 30 and chemical formulations have been significant, [30] [31] [32] but to achieve therapeutic levels, nanogram quantities are needed. Thus far, this has not been achieved with other plasmid-based muscle delivery systems.
Electroporation has been shown to be a powerful gene delivery method for muscle, as well as other tissues, [33] [34] [35] and several groups have observed a two-to three-log increase in gene expression level. [15] [16] [17] We demonstrated for the first time that electroporation delivery of as little as 10 g of IFN-␣ DNA plasmid significantly reduced SCCVII tumor growth in mice and increased survival time (P Ͻ 0.05) compared with syringe needle injection only.
A high dose (40 g) of IFN-␣ DNA plasmid delivered via electroporation led to a longer survival time than that of the low dose (10 g) using electroporation delivery (Figure 2b ). However, a high dose delivered by syringe needle injection alone did not improve therapeutic efficacy (Figure 2a) . This was probably due to the fact that it was only with electroporation that a high level of IFN-␣ expression (Figure 3) and, subsequently, a reduced 
(a) Comparison of growth inhibition of SCCVII tumors by IFN-␣ gene administered intramuscularly with or without electroporation. Treatment was initiated when the tumor was around 15 mm 3 (n = 5). (b) Comparison of Kaplan-Meier survival curves of the SCCVII tumor-bearing mice treated with different doses of IFN-␣ with or without electroporation. Treatment was initiated when the tumor was approximately 40 mm 3 . Two mice in the group treated with 40 g of IFN-␣ DNA plasmid via pulse survived more than 45 days (n = 10). (c) Inhibition of tumor growth by delayed IFN-␣ treatment administered by intramuscular electroporation. Treatment was initiated when tumor was approximately 30-40 mm
3 (n = 5).
Gene Therapy
Figure 3 Western blot analysis of IFN-␣ expression in muscle extract and serum after injection, with or without electroporation, of IFN-␣ DNA plasmid or control empty plasmid. Ten micrograms of DNA plasmid in a volume of 10 l were delivered to the hind limb tibialis muscle with or without electroporation (CP, control empty DNA plasmid). The loading sample was a pool of three individual mice, with 10 g of total protein from muscle and 10 l of serum used for each sample. The light chain of immunoglobin (IgL) serves as an internal control, and the 19 kD protein is IFN-␣. (a) Western blot analysis of the serum and muscle extracts obtained on day 3 after injection, with or without electroporation, of 40 g of IFN-␣ DNA or control empty DNA plasmid. (b) Western blot analysis of serum samples obtained on days 1, 3 and 7 after a single injection, with or without electroporation, of 10 g of IFN-␣ DNA plasmid.
number of vessels in tumor tissue ( Figure 4B ) were only achieved with electroporation. In our series of experiments, we discovered that Mig and IP-10 genes were up-regulated by IFN-␣ (Figure 4 ). Mig and IP-10 have been known to inhibit angiogenesis and to chemo-attract monocytes, NK cells, and activated T cells. [23] [24] [25] [26] [27] [28] Thus, inhibition of SCCVII tumor growth by intramuscular electro-injection of IFN-␣ may be due to both an immune stimulation and an antiangiogenic effect. This theory is supported by the observation that electroinjection of IL-12 gene, known to induce Mig and IP-10, was able to inhibit SCCVII tumor growth ( Figure 6 ). Our hypothesis is also supported by the fact that neither the antiangiogenic endostatin gene nor the T cell proliferation-stimulating IL-2 gene alone demonstrated any significant therapeutic efficacy, with or without electroporation delivery. However, we plan to conduct additional studies that should further substantiate our hypothesis.
Although it has been shown that intramuscular injection of IFN-␣ gene using a syringe needle significantly inhibited B16F10 melanoma and glioma 261 growth in mice and reduced Cloudman melanoma tumor growth in vivo, 14 we were unable to obtain similar results using the SCCVII tumor model with injection only of either a high or low dose of IFN-␣ DNA using a syringe needle ( Figure  2) . Likewise, although it has been reported that intramuscular injection of endostatin gene reduced the number of Renca metastasis nodules in the lung, as well as primary tumor growth, 36 our data using the SCCVII tumor model suggested that intramuscular delivery of endostatin gene with or without electroporation could not slow the tumor growth rate. Our findings might differ from those reported in the literature because the SCCVII tumor is more aggressive than the other tumor models tested.
In conclusion, electroporation delivery of gene to muscle is simple, economic, directly targeted, and safe. We anticipate that the therapeutic efficacy will be significant when the appropriate gene is chosen. Thus, this will be the most attractive strategy for nonviral gene delivery.
Materials and methods

Experimental animals
Female 6-to 8-week-old C3H/HeJ mice weighing 18-20 g were purchased from Jackson Laboratories (Bar Harbor, ME, USA). The C3H/HeJ strain was used because this strain can host SCCVII tumors. Animals were maintained under NIH guidelines at 37°C, 12-h day/night cycle, and 80% relative humidity.
Gene construct and plasmid manufacture
The reporter genes, luciferase and alkaline phosphatase, driven by the CMV (cytomegalovirus) promoter, have previously been described. 30 The therapeutic gene constructs, which express endostatin, IL-2, IL-12, and IFN-␣, were provided by Valentis (The Woodlands, TX, USA), and the structures of the constructs are depicted in previous publications. 10, 36, 37 The control construct is the result of a deletion of IFN-␣ cDNA.
All plasmids were manufactured with the Qiagen Giga Endo-Free Prep Kit (Valencia, CA, USA). Residual salts were removed from the plasmid by dialysis against sterile water (USP) with a Millipore dialysis tube (Bedford, 405 MA, USA). The purity of the plasmid was confirmed using 1% agarose gel electrophoresis. DNA concentration was measured by absorption at 260 nm. The percentage of supercoiled DNA to total DNA and the OD 260/280 ratios of these plasmid preparations ranged from 80 to 90% and 1.5 to 1.7, respectively. SCCVII tumor generation in mice and tumor growth monitoring SCCVII is a spontaneously arising murine squamous cell carcinoma that has been well characterized in C3H/HeJ mice. 38, 39 We obtained this cell line from Dr Candice Johnson at the University of Pittsburgh (Pittsburgh, PA, USA). The cells were maintained in AIM-V growth medium with 10% fetal bovine serum (Gibco, Grand Island, NY, USA). Mice were subcutaneously inoculated with 1 × 10 5 SCCVII cells in a volume of 30 l. When tumors reached a measurable size (2-3 mm in diamater), mice were randomly divided into groups of five each. Mice bearing tumors that were 30% greater or smaller than the average were excluded from the experimental group.
Seven to 9 days after tumor inoculation, when tumor volume was about 15-30 mm 3 , we delivered the IFN-␣ gene or control plasmid to the left hind tibialis muscle, with or without electroporation. Three administrations were performed once a week, and a different hind limb muscle was used for each administration, proceeding from the left hind tibialis to the right hind tibialis and then back to the left hind tibialis.
Tumor growth was monitored twice a week with a caliper as soon as the treatment started. Tumor volume was calculated with the formula: V = (Dd 2 /4), 40 where V is volume, D is maximum tumor diameter, and d is diameter at 90°to D. At the completion of the study, mice were killed with carbon dioxide narcosis.
Electroporation delivery of DNA plasmid Purified plasmids were formulated in 150 mm sodium chloride, as described previously. 30 Animals were anesthetized by intraperitoneal administration of a mixture of ketamine (42.8 mg/ml), xylazine (8.6 mg/ml), and acepromazine (1.4 mg/ml) at a dose of 1.8-2.0 ml/kg. A 10 l formulation containing 10 g DNA was injected intramuscularly into the tibialis muscle of each animal with a 28.5-gauge needle. Immediately after injection, animals undergoing electroporation had two heads of a caliper electrode positioned at two sides of the leg with contact of the skin. The pulse was applied to the leg through the electrode with a power supply device (BTS EC830; Genetronics, San Diego, CA, USA). The parameters were two 25-ms pulses of 375 V/cm. 29 Bleeding and SEAP assay Mice were bled from the retro-orbital plexus. The blood was centrifuged at 4000 r.p.m. for 5 min, and serum was collected for the SEAP assay with the use of serum separators (Becton Dickinson, Franklin Lakes, NJ, USA), as described in our previous publication. 30 Muscle protein extraction and luciferase assay Lyophilized muscles were homogenized with silica beads for 2 min with the use of a Mini-BeadBeater (BioSpec Products, Bartlesville, OK, USA). One milliliter of luciferase cell lysis buffer (Promega, Madison, WI, USA) was added to the powdered muscle, and the samples were homogenGene Therapy ized for another 3 min. The suspension was centrifuged at 14000 r.p.m. for 15 min, and the supernatant was assayed for total protein and luciferase activity, as described in a previous publication. 30 Total protein was determined with the BCA protein assay kit (Pierce, Rockford, IL, USA). Luciferase was determined with the luciferase assay kit from Promega.
Western blot analysis
Muscle extract and serum were used for Western blot analysis to determine IFN-␣ gene expression. Briefly, 10 g of total protein from muscle extract or 10 l of serum was subjected to SDS-PAGE in a gradient gel, and the protein was transferred to a nitrocellulose membrane (Millipore). Immunoblotting was performed with a primary anti-IFN-␣ polyclonal antibody (PBL Biomedical Laboratories, New Brunswick, NJ, USA) and anti-rabbit secondary antibody conjugated with horseradish peroxidase (HRP). The HRP signal was generated by incubation with a chemiluminescence detection kit (Amersham, Alameda, CA, USA) and exposure on X-ray film.
Immunostaining analysis
Fifty cubic millimeters of tumor tissue were used for frozen-block preparation. The mold in which the tissue was arranged in the frozen embedding medium (TissueTek; Sakura Finetek, Torrance, CA, USA) was plunged into 2-methylbutane prechilled in liquid nitrogen, until the block almost solidified. The frozen tissue blocks were stored at −70°C until sectioning. A 5-m section was cut and fixed with cold acetone (−20°C) for 2 min. The sections were rinsed with phosphate-buffered saline (PBS) to remove frozen mounting media and blocked with 5% goat serum. The protocol was provided by PharmaGen (San Diego, NJ, USA). The primary antibodies applied to the sections were anti-CD31 (1:200) and anti-CD8 + T cell antibody (1:50), which were removed after incubation for 1 h. After rinsing of the slides three times, the diluted biotinylated secondary antibody (1:400 dilution for anti-CD31 staining and 1:200 for anti-CD8 staining) was applied and incubated for 30 min. Streptavidin/HRP was then applied after three rinses with PBS and incubated for another 30 min. After rinsing of the slides, DAB was applied for 5-10 min, followed by three rinses in water. All the antibody and immunostaining reagents were purchased from PharmaGen. Hematoxylin and bluing solutions (Fisher Scientific, Pittsburgh, PA, USA) were used for counterstaining the slides.
Probe isolation by reverse transcriptase polymerase chain reaction (RT-PCR) and Northern blot analysis of Mig and IP-10 expression Three days after the third administration of gene therapy, mice were killed and tumors were harvested for total RNA preparation with RNAzol (TelTest, Friendswood, TX, USA). Residual DNA was removed from RNA by incubating the RNA extract with DNase at 37°C for 20 min. To obtain IP-10, Mig, and GAPDH templates for probes, 5 g of total RNA was subjected to RT with oligodT primer. Five percent of the cDNA from the RT reaction was used to amplify the target gene with Mig-, IP-10-, or GAPDH-specific primers for 30 cycles at the following conditions: 94°C, 30 s; 65°C, 30 s; 72°C, 45 s. The PCR product was isolated from agarose gel. The Northern blot analysis was processed, as described pre-viously, 41 with the probes of Mig, IP-10, and actin. Each probe was randomly prime-labeled (DECA Primer II DNA Labeling Kit; Ambion, Austin, TX, USA) with 32 PdCTP (3000 Ci/mmol; Amersham Pharmacia Biotech, Piscataway, NJ, USA). Approximately 10 g of total RNA from tumor tissues was subjected to 1% agarose-formaldehyde gel electrophoresis at 100 V for 2 h. The RNA was transferred to a positively charged nylon membrane (Boehringer Mannheim, Indianapolis, IN, USA) and prehybridized and hybridized at 42°C in a hybridization buffer purchased from Ambion. Hybridization of the same filters with a probe for ␤-actin was used as an internal control for RNA loading, and methylene blue staining was used to determine the relative sizes of hybridized RNA. 41 The Northern blot results were quantified by scanning the expression signal intensity with a PhosphorImager analyzer (Model 445 SI; Molecular Dynamics, Sunnyvale, CA, USA).
Statistical analysis
Experimental data were analyzed by one-way analysis of variance (ANOVA), with measurement of tumor growth or enzyme activity as the main outcome measured. Means of individual treatments were compared with Student's t test when the main effect was significant. Statistical significance was defined as a P Ͻ 0.05.
